

# SEQUENCE LISTING

<110> LOUVAIN, Virginie  
 BIANCHINI, Elsa  
 MARQUE, Pierre-Emmanuel  
 CALMEL-TAREAU, Claire  
 AIACH, Martine  
 LE BONNIEC, Bernard

<120> THROMBIN CLEAVABLE FACTOR X ANALOGUES

<130> 263989US0PCT

<140> US 10/518,390

<141> 2004-12-30

<150> PCT/EP03/07793

<151> 2003-06-30

<150> FR 02 08299

<151> 2002-07-03

<160> 31

<170> PatentIn version 3.1

<210> 1

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> Factor X activating site

<400> 1

Leu Thr Arg Ile Val Gly  
 1 5

<210> 2

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic Peptide

<400> 2

Met Pro Arg Ser Phe Arg  
 1 5

<210> 3

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic Peptide

<400> 3

Val Pro Arg Ser Phe Arg  
1 5

<210> 4

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic Peptide

<400> 4

Thr Arg Arg Ser Val Gly  
1 5

<210> 5

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic Peptide

<400> 5

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn  
1 5 10

<210> 6

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic Peptide

<400> 6

Glu Asp Gln Val Asp Pro Arg Leu Ile Asp Gly Lys  
1 5 10

<210> 7

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> Variant of Factor X activating site

<400> 7

Val Pro Arg Ile Val Gly  
1 5

<210> 8  
 <211> 6  
 <212> PRT  
 <213> Artificial sequence  
  
 <220>  
 <223> Variant of Factor X activating site  
  
 <400> 8

Val Pro Arg Ile Phe Gly  
 1 5

<210> 9  
 <211> 6  
 <212> PRT  
 <213> Artificial sequence  
  
 <220>  
 <223> Variant of Factor X activating site  
  
 <400> 9

Val Pro Arg Ala Val Gly  
 1 5

<210> 10  
 <211> 6  
 <212> PRT  
 <213> Artificial sequence  
  
 <220>  
 <223> Variant of Factor X activating site  
  
 <400> 10

Val Pro Arg Ile Phe Arg  
 1 5

<210> 11  
 <211> 6  
 <212> PRT  
 <213> Artificial sequence  
  
 <220>  
 <223> Variant of Factor X activating site  
  
 <400> 11

Val Pro Arg Ser Val Gly  
 1 5

<210> 12  
 <211> 6  
 <212> PRT

<213> Artificial sequence

<220>

<223> Variant of Factor X activating site

<400> 12

Val Pro Arg Ser Phe Arg

1 5

<210> 13

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 13

acgcggatcc gcgatggggc gcccaactgca 30

<210> 14

<211> 68

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 14

tcccccgagg gatcagttca ggtcttcctc gctgatcagc ttctgctcct ttaatggaga 60

ggacgtta 68

<210> 15

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 15

tatgcgtggg ctggagcaac c 21

<210> 16

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 16

ttattaggac aaggctggtg gg 22

<210> 17  
 <211> 21  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 17  
 cttcccatca atgagccgcg g 21

<210> 18  
 <211> 42  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 18  
 ccgcggctca ttgatgggaa ggatggcgac cagtgtgaga cc 42

<210> 19  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 19  
 aggggcgaca acaacgtgcc taggatcgtg ggcggccagg aatgcaag 48

<210> 20  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 20  
 cttgcattcc tggccgcca cgatcctagg cacgttggtg tcgcccct 48

<210> 21  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 21  
 aggggcgaca acaacgtgcc taggatcttc ggcggccagg aatgcaag 48

<210> 22

<211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 22  
 cttgcattcc tggccgcca agatcctagg cacgttggtg tcgccct 48  
  
 <210> 23  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 23  
 agggcgaca acaacgtgcc taggatcttc agggccagg aatgcaag 48  
  
 <210> 24  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 24  
 cttgcattcc tggcccctga agatcctagg cacgttggtg tcgccct 48  
  
 <210> 25  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 25  
 agggcgaca acaacgtgcc taggagcttc agggccagg aatgcaag 48  
  
 <210> 26  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 26  
 cttgcattcc tggcccctga agctcctagg cacgttggtg tcgccct 48  
  
 <210> 27  
 <211> 29

<212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 27  
 caacgtgcct aggagcgtgg gcggccagg 29  
  
 <210> 28  
 <211> 29  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 28  
 cctggccgcc cacgctccta ggcacgttg 29  
  
 <210> 29  
 <211> 55  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 29  
 cctgagaggg gcgacaacaa cgtgcctagg gccgtgggcg gccaggaatg caagg 55  
  
 <210> 30  
 <211> 55  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> PCR primer  
  
 <400> 30  
 ccttgcattc ctggccgccc acggccctag gcacgttggt gtcgcccctc tcagg 55  
  
 <210> 31  
 <211> 6  
 <212> PRT  
 <213> Artificial sequence  
  
 <220>  
 <223> Variants of Factor X activating site  
  
 <220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa= Ala, Cys, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg,  
 Ser, Thr, Val, Trp ou Tyr

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa= Val, Ile, Leu ou Phe

<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> Xaa= Gly, Asn ou His

<400> 31

Xaa Pro Arg Ala Xaa Xaa  
1 5